Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
Lorenzo delSorbo
60 participants
Oct 20, 2025
INTERVENTIONAL
Conditions
Summary
Acute hypoxemic respiratory failure (AHRF) happens when the lungs are unable to absorb enough oxygen. The bloodstream is deprived of oxygen which can eventually lead to more severe conditions like multi-organ failure (MOF) and death. AHRF accounts for over 30% of patients to critical care units, thus novel treatments are sorely needed. Research has shown that blood levels of the inflammatory biomarker Interleukin-6 (IL-6) may be a reliable marker for predicting which patients with AHRF will progress into requiring intensive care unit (ICU) admission, MOF, and eventually death. IL-6 levels were shown to reliably peak several days before MOF, ICU admission, and death. Thus, the investigators believe that by identifying patients before the peak of their IL-6 levels, they will be able to administer early treatment to prevent the patient's condition from worsening. The aim of this study is to test the feasibility of a treatment strategy for AHRF based on IL-6 measurement in patients who are admitted to hospital care with AHRF. Patients who are eligible for the study will have their plasma IL-6 levels measured over 2 days. Patients with elevated IL-6 levels will be randomized into 1 of 3 treatment groups: standard of care only, standard of care plus a single IV infusion of Tocilizumab, or standard of care plus treatment with oral Dexamethasone for 10 days. Patients will then be observed till discharge or up to 28 days, and a follow-up phone interview will be conducted 6 months of the end of the observation period.
Eligibility
Inclusion Criteria3
- Age ≥18 years
- Presence of new onset of respiratory symptoms in the previous 14 days upon presentation at the emergency department. Respiratory symptoms are characterized by at least one of the following: cough, dyspnea, or requirement of oxygen supplementation
- Requirement of inpatient hospital management
Exclusion Criteria25
- Inability to provide informed consent
- Patients with known contraindications to dexamethasone or tocilizumab, or any of their components
- Allergic reaction to tocilizumab or other monoclonal antibodies
- Patients who are using azathioprine or cyclophosphamide
- Active tuberculosis infection
- Patients who have active hepatic disease or hepatic impairment
- ALT or AST \>3x upper limit of normal
- Neutrophil count \<1000/mcl
- Platelet count \<50,000/mm3
- Hemoglobin (Hb) below 8.5 g/dL,
- White blood cell count (WBC) below 3000/mm3
- Absolute Neutrophil Count (ANC) below 2.0 x 109/L
- absolute lymphocyte count below 500/mm3
- total bilirubin above ULN
- Triglycerides (TG) above 10 mmol/L (above 900 mg/dL)
- Serum creatinine above 1.4 mg/dL in female patients and above 1.6 mg/dL in male patients
- Patients already receiving systemic steroids, monoclonal antibodies or other immunosuppressive medications at the time of presentation
- Inability to comply with the regulations to avoid conception within 28 days after enrollment
- Admission to ICU prior to randomization
- Immediate need for intubation
- Imminent death
- Clinical team refusal
- Participation in other drug clinical trials (this criterion will be discussed with the PI)
- Reaching \>72h since hospital admission
- Pregnancy (positive pregnancy test) or breastfeeding (which is a contraindication to tocilizumab)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Subjects randomized to the tocilizumab arm will receive a single intravenous (IV) infusion of tocilizumab, given over 1 hour. The tocilizumab will be given at a dosage of 4mg per kg of body weight, up to a maximum dose of 400 mg.
Subjects randomized to the dexamethasone arm will receive 6 mg of dexamethasone per day, for up to 10 days, or until discharged from the hospital. Dexamethasone will be given in tablet form orally (by mouth) or through an equivalent method.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07334379